Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

p>

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that pixantrone could cause cumulative heart damage, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room


    Investors Contact:

    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... November 25, 2014 The Pittcon marketing ... official conference and exposition mobile app, ... download in the App Store for iOS and Android ... resource tool before, during and after the event. It ... on exhibiting companies, technical sessions, Conferee Networking sessions and ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... June 23 Replidyne, Inc.,(Nasdaq: RDYN ) today ... with Asubio Pharma Co., Ltd. for faropenem medoxomil (faropenem).,In ... it has,terminated its supply agreement with Asubio Pharma Co., ... These decisions were made as a,result of the Company ...
... Web-based programs give sponsors easy-to-use tools to store, mine ... transfer knowledge base to ensure enrollment success, ... recruitment technology leader, announced the release of a new,product, ... support in-house recruitment capabilities for clinical,trial sponsors. The goal ...
... Ariz., June 23 MedPredict has published ... insight for pharma and,biotech companies hoping to ... The report, entitled "Thought Leader Insight & ... with a panel of,specialists in anesthesiology, psychiatry, ...
Cached Biology Technology:Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict 2
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... 2009)A minimally invasive interventional radiology treatmentthat safely and ... herniated diskswill become standard in the United States ... the Society of Interventional Radiology,s 34th Annual Scientific ... examined just how ozone relieves the pain associated ...
... once a week displayed higher cognitive skills at the age of ... a study of nearly 4,000 teenagers published in the March issue ... a week was enough to increase combined, verbal and visuospatial intelligence ... more than once a week increased them by just under 11 ...
... strokes has taken a significant step forward today (09 ... brain tissue in rats. The team of scientists ... Council (BBSRC) and led by Dr Mike Modo of ... work, carried out at the Institute of Psychiatry and ...
Cached Biology News:Oh, my aching back: Give me a shot of ozone 2Oh, my aching back: Give me a shot of ozone 3Teenage boys who eat fish at least once a week achieve higher intelligence scores 2Teenage boys who eat fish at least once a week achieve higher intelligence scores 3Stem cells replace stroke-damaged tissue in rats 2
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
Biology Products: